1.广州中医药大学中药学院,广东 广州 510006
2.中山大学药学院,广东 广州 510006
邓金辉(1994年生),男;研究方向:天然药物活性成分的结构修饰;E-mail:2946291608@qq.com
黄仪有(1989年生),男;研究方向:药物化学与结构生物学;E-mail:huangyy287@mail.sysu.edu.cn
何细新(1972年生),男;研究方向:天然药物化学;E-mail:mark07@gzucm.edu.cn
纸质出版日期:2022-05-25,
网络出版日期:2021-06-05,
收稿日期:2021-02-08,
录用日期:2021-04-28
扫 描 看 全 文
邓金辉,黄悦,梁津豪等.α-倒捻子素衍生物合成及其抑制磷酸二酯酶4活性研究[J].中山大学学报(自然科学版),2022,61(03):53-61.
DENG Jinhui,HUANG Yue,LIANG Jinhao,et al.Synthesis of α-mangostin derivatives and evaluation of their inhibitory activities towards phosphodiesterase 4[J].Acta Scientiarum Naturalium Universitatis Sunyatseni,2022,61(03):53-61.
邓金辉,黄悦,梁津豪等.α-倒捻子素衍生物合成及其抑制磷酸二酯酶4活性研究[J].中山大学学报(自然科学版),2022,61(03):53-61. DOI: 10.13471/j.cnki.acta.snus.2021C002.
DENG Jinhui,HUANG Yue,LIANG Jinhao,et al.Synthesis of α-mangostin derivatives and evaluation of their inhibitory activities towards phosphodiesterase 4[J].Acta Scientiarum Naturalium Universitatis Sunyatseni,2022,61(03):53-61. DOI: 10.13471/j.cnki.acta.snus.2021C002.
以
α-
倒捻子素为先导化合物设计合成一系列衍生物并测试其对磷酸二酯酶4 (PDE4,phosphodiesterase 4)的抑制活性。首先
α-
倒捻子素在DDQ作用下氧化环合得到中间体
1
,然后经烷基化、还原、水解、酰化等化学反应合成6-位取代的目标化合物;采用[
3
H]标记液体闪烁计数法测试了衍生物体外抑制PDE4活性。最终设计、合成了11个目标化合物,其结构经
1
H NMR、
13
C NMR、HRMS等波谱数据分析确证。活性测试结果表明7个化合物 (
4a
、
4b
、
5
、
6
、
8
、
11
和
13
)的PDE4抑制活性强于
α
-倒捻子素,其中化合物
5
的活性最强 (IC
50
=247 nmol/L)。
Derivatives of
α
-mangostin were designed and synthesized in this study,and their phosphodiesterase 4(PDE4) inhibitory activities were evaluated
in vitro
.The initial substrate
α
-mangostin was converted into the cyclized compound
1
, followed by eleven desired compounds were prepared by alkylation, hydrolysis, acylation reaction and other methods. The structures of the desired compounds were confirmed by
1
H NMR,
13
C NMR and ESI-(HR)MS. The PDE4 inhibitory activities of these compounds were evaluated
in vitro
by [
3
H] liquid scintillation counting method. Among the desired compounds, compounds
4a
,
4b
,
5
,
6
,
8
,
11
and
13
showed stronger PDE4 inhibition activity than
α
-mangostin. Compound
5
exhibited potential PDE4 inhibitory activity with the IC
50
values of 247 nmol/L.
α-倒捻子素衍生物磷酸二酯酶4抑制剂
α-mangostinderivativesphosphodiesterase 4(PDE4)inhibitor
BENDER A T, BEAVO J A. Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use[J]. Pharmacological Reviews, 2006, 58(3): 488-520.
KERAVIS T, LUGNIER C. Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments[J]. British Journal of Pharmacology, 2012, 165(5): 1288-1305.
CONTI M, RICHTER W, MEHATS C, et al. Cyclic AMP-specific PDE4 phosphodiesterases as critical components of cyclic AMP signaling[J]. Journal of Biological Chemistry, 2003, 278(8): 5493-5496.
LI H, ZUO J, TANG W. Phosphodiesterase-4 inhibitors for the treatment of inflammatory diseases[J]. Frontiers in Pharmacology, 2018, 9: 1048.
SAKKAS L I, MAVROPOULOS A, BOGDANOS D P. Phosphodiesterase 4 inhibitors in immune-mediated diseases: mode of action, clinical applications, current and future perspectives[J]. Current Medicinal Chemistry, 2017, 24(28): 3054-3067.
BLOKLAND A, HECKMAN P, VANMIERLO T, et al. Phosphodiesterase type 4 inhibition in CNS diseases[J]. Trends in Pharmacological Sciences, 2019, 40(12): 971-985.
ESKANDARI N, MIRMOSAYYEB O, BORDBARI G, et al. A short review on structure and role of cyclic-3',5'-adenosine monophosphate-specific phosphodiesterase 4 as a treatment tool[J]. Journal of Research in Pharmacy Practice, 2015, 4(4): 175-181.
PINNER N A, HAMILTON L A, HUGHES A. Roflumilast: A phosphodiesterase-4 inhibitor for the treatment of severe chronic obstructive pulmonary disease[J]. Clinical Therapeutics, 2012, 34(1): 56-66.
PEREZ-ASO M, MONTESINOS M C, MEDIERO A, et al. Apremilast, a novel phosphodiesterase 4 (PDE4) inhibitor, regulates inflammation through multiple cAMP downstream effectors[J]. Arthritis Research & Therapy, 2015, 17: 249.
KEATING G M. Apremilast: A review in psoriasis and psoriatic arthritis[J]. Drugs, 2017, 77(4): 459-472.
CHEAPE A C, MURRELL D F. 2% Crisaborole topical ointment for the treatment of mild-to-moderate atopic dermatitis[J]. Expert Review of Clinical Immunology, 2017, 13(5): 415-423.
LIPWORTH B J. Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease[J]. The Lancet, 2005, 365(9454): 167-175.
WANG M, ZHANG K, QINLAN G U, et al. Pharmacology of mangostins and their derivatives: A comprehensive review[J]. Chinese Journal of Natural Medicines, 2017, 15(2): 81-93.
YIN Q, WU Y J, PAN S, et al. Activation of cholinergic anti-inflammatory pathway in peripheral immune cells involved in therapeutic actions of α-mangostin on collagen-induced arthritis in rats[J]. Drug Design, Development and Therapy, 2020,14:1983-1993.
YANG Z, YIN Q, OLATUNJI O J, et al. Activation of cholinergic anti-inflammatory pathway involved in therapeutic actions of α-mangostin on lipopolysaccharide-induced acute lung injury in rats[J]. International Journal of Immunopathology and Pharmacology, 2020, 34: 1-12.
YAO L, GU X, SONG Q, et al. Nanoformulated alpha-mangostin ameliorates Alzheimer's disease neuropathology by elevating LDLR expression and accelerating amyloid-beta clearance[J]. Journal of Controlled Release, 2016, 226: 1-14.
LIANG J, HUANG Y Y, ZHOU Q, et al. Discovery and optimization of α-mangostin derivatives as novel PDE4 inhibitors for the treatment of vascular dementia[J]. Journal of Medicinal Chemistry,2020, 63(6): 3370-3380.
0
浏览量
1
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构